Name of Mechanism Indications Contraindication Side Effects Nursing

Drug of Action Responsibilities

Generic Magnesium  To  Parenteral CNS: Before:
Name: Sulfate is prevent administrati drowsiness  Take an
Magnesium essential / on , depress appropriate
Sulfate element for control contraindica reflexes, seizure precaution.
muscle and seizure ted inpatient placid
Brand nerve in pre- with heart paralysis, During:
Name: transmission. eclamp block hypotherm  Check
Magnesium Extracellular sia myocardial ia Magnesium
Sulfate fluid damage. CV: level repeat
levels:1.5  To hypotensio doses.
Dosage: – manage  Use n, flushing Disappeara
>Preeclampsi 2.5 mg/L. Mg preter cautiously bradycardi nce of knee,
a depresses m inpatients a, Jerl and
woman: 4g the CNS and labor. with circulatory patellar
IV in 250mL controls impaired collapse, reflexes is a
D5W with convulsion by renal depress sign of
normal blocking function. cardiac impeding
saline and 4- release of function magnesium
5 g. deep IM acetylcholine  Use Skin: toxicity.
into buttock at the cautiously in diaphoresis
alternate in myoneural pregnant  Monitor
every 4hrs., junction. woman urine intake
P.R.N 4g I.V. Also, mg during labor. and output.
Lodding dose decrease
then 1-2 q sensitivity of After:
hr. as I.V motor end
 Observe
infusion. plate to
neonates
Dose should acetylcholine
for signs of
not exceed and
magnesium
30-40 g. daily decreases the toxicity.
excitability of
the mother
Classification membrane.
: as a laxative
Anticonvulsa it acts in the
nt small and
large
intestine to
attract and
retain water
in the
intestinal
lumen,
increasing
intraluminal
pressure, also
releases
cholecystokin
in
Drug Name Dosages Therapeutic Indications Adverse Contraindicati Nursing
Actions effects ons Responsibilities
Generic Drug: PO Betamethaso Systemic Sodium and Hypersensitivi Assessment
Betamethasone Allergic and ne is a administration fluid ty; systemic
inflammatory corticosteroi retention, fungal or  History
Brand Name: disorders; d with mainly  Hypercal potassium acute (Systemic
Celestone, congenital glucocorticoi cemia and calcium infections administration):
Celestone adrenal d activity. It associate depletion. Infections, fungal
Soluspan, hyperplasia prevents and d with Muscle infections,
Betaject, 0.5-5mg/day. by controlling cancer wasting, amebiasis, vaccinia
Betamethasone IM the rate of  Short- weakness, and varicella, and
IM/PO Allergic and protein term osteoporosi antibiotic-resistant
inflammatory synthesis, manage s.GI infections; kidney
Classification: disorders as depressing ment of disturbance or liver disease;
Corticosteroids betamethasone the migration inflamm s and hypothyroidism;
Na phosphate of atory bleeding. ulcerative colitis
and polymorphon and Increased with impending
betamethasone uclear allergic appetite perforation;
acetate: leukocytes disorders and delayed diverticulitis; active
Initial:0.25-9 and , such as wound or latent peptic
mg/day in1-2 fibroblasts, rheumat healing; ulcer;
divided doses. and reversing oid hirsutism, inflammatory
Ophth Allergic capillary arthritis, bruising, bowel disease;
and permeability collagen striae, acne; CHF; hypertension;
inflammatory and diseases raised thromboembolic
conditions of lysosomal (eg, SLE), intracranial disorders;
the eye as 0.1% stabilization. dermatol pressure, osteoporosis;
soln: As Na ogic headache, seizure disorders;
phosphate: diseases depression, diabetes mellitus;
Instill 1-2 hrly psychosis,
until symptoms (eg, menstrual lactation
are controlled. pemphig irregularitie
As0.1% oint: us), s.  Physical:
As Na status Hyperglyce Baseline weight, T,
phosphate: asthmati mia, reflexes and grip
Apply2-4 cus, and DM. strength, affect
times/day or at autoimm Suppression and orientation, P,
night w/ the une of pituitary- BP, peripheral
eyedrops. disorders adrenocorti perfusion,
Topical Skin cal axis. prominence of
disorders As  Hematol Growth superficial veins,
dipropionate ogic retardation Rand adventitious
(0.05%) or disorders in children sounds, serum
valerate (0.025 : (prolonged electrolytes, blood
or 0.1%): Apply Thrombo therapy). glucose
as directed cytopeni Increased
a susceptibilit Interventions
purpura, y for
erythrobl infections. Systematic use
astopeni Topical use:
a Dermal
 Give daily
atrophy,
dose 9am
 Ulcerativ local
to mimic
e colitis, irritation,
normal
acute folliculitis,
peak
exacerba hypertricho
corticoste
tions of sis.
roid blood
MS, and Inhalation:
levels.
palliation Hoarseness,
 Increase
in some candidiasis
dosage
leukemia of mouth
when
s and and
patient is
lympho throat.
subject to
mas Topical
stress
application
 Taper
 Trichinos to the eye:
doses
is with Corneal
when
neurolog ulcers,
discontinu
ic or raised IOP
ing high
myocardi and reduced
dose or
al visual
long-term
involvem acuity.
therapy
ent Intradermal
 Do not
injection:
give live
Local
virus
hypopigmen vaccines
tation of with
deeply immunos
pigmented uppressiv
skin. Intra- e doses of
articular corticoste
injection: roids.
Joint
damage, Topical
fibrosis, esp. dermatologic
in load preparations
bearing
joints
Examine area for
infections and
skin integrity
before application

 Administ
er
cautiousl
y to
pregnant
patients’
topical
corticost
eroids
have
caused
teratoge
nic
effects
and can
be
absorbed
from
systemic
site.